Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Smith & Nephew Snats ( (SNN) ) has shared an update.
As of 31 January 2026, Smith & Nephew plc reported a total issued share capital of 877,724,845 ordinary shares of US$0.20 each, of which 27,912,707 are held in treasury. This leaves 849,812,138 ordinary shares carrying one voting right each, a figure the company highlighted on 2 February 2026 as the key denominator for investors assessing whether they must disclose shareholdings or changes in holdings under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, ensuring clarity for shareholders and the market on current voting rights and capital structure.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company listed in both London and New York, focused on orthopaedics, sports medicine, ENT, and advanced wound management products for healthcare providers worldwide.
Average Trading Volume: 704,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: $14.44B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.